Clinical Trial Update: Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating axicabtagene ciloleucel in combination with rituximab for refractory large B-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)
• Rituximab (rituximab)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Refractory Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-02-20